Tambocor Dispute, FTC Report May Keep Generic Drugs On Congress' Agenda

A dispute between Par and Barr over generic exclusivity for flecainide reflects the continued complexities in the Waxman/Hatch process that could drive Congressional action over the next 18 months.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet